WO2002060533A3 - Pharmaceutical compositions containing beta-mimetic agents and having few side-effects - Google Patents
Pharmaceutical compositions containing beta-mimetic agents and having few side-effects Download PDFInfo
- Publication number
- WO2002060533A3 WO2002060533A3 PCT/EP2002/000704 EP0200704W WO02060533A3 WO 2002060533 A3 WO2002060533 A3 WO 2002060533A3 EP 0200704 W EP0200704 W EP 0200704W WO 02060533 A3 WO02060533 A3 WO 02060533A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical compositions
- effects
- compositions containing
- few side
- containing beta
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002436510A CA2436510A1 (en) | 2001-02-01 | 2002-01-24 | Pharmaceutical compositions with few side effects |
AU2002252981A AU2002252981A1 (en) | 2001-02-01 | 2002-01-24 | Pharmaceutical compositions containing beta-mimetic agents and having few side-effects |
EP02722033A EP1357976A2 (en) | 2001-02-01 | 2002-01-24 | Pharmaceutical compositions having few side-effects |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10104370.8 | 2001-02-01 | ||
DE10104370A DE10104370A1 (en) | 2001-02-01 | 2001-02-01 | Medicinal compositions with fewer side effects |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002060533A2 WO2002060533A2 (en) | 2002-08-08 |
WO2002060533A3 true WO2002060533A3 (en) | 2002-12-12 |
Family
ID=7672383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/000704 WO2002060533A2 (en) | 2001-02-01 | 2002-01-24 | Pharmaceutical compositions containing beta-mimetic agents and having few side-effects |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1357976A2 (en) |
AU (1) | AU2002252981A1 (en) |
CA (1) | CA2436510A1 (en) |
DE (1) | DE10104370A1 (en) |
WO (1) | WO2002060533A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9056100B2 (en) | 1999-07-14 | 2015-06-16 | Almirall, S.A. | Quinuclidine derivatives and medicinal compositions containing the same |
US9254262B2 (en) | 2008-03-13 | 2016-02-09 | Almirall, S.A. | Dosage and formulation |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7214687B2 (en) | 1999-07-14 | 2007-05-08 | Almirall Ag | Quinuclidine derivatives and medicinal compositions containing the same |
US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
BRPI0614290A2 (en) | 2005-08-08 | 2011-03-22 | Argenta Discovery Ltd | bicyclo [2.2.1] hept-7-ylamine derivatives and their uses |
ES2298049B1 (en) | 2006-07-21 | 2009-10-20 | Laboratorios Almirall S.A. | PROCEDURE FOR MANUFACTURING BROMIDE OF 3 (R) - (2-HIDROXI-2,2-DITIEN-2-ILACETOXI) -1- (3-PHENOXIPROPIL) -1-AZONIABICICLO (2.2.2) OCTANO. |
EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19827178A1 (en) * | 1998-06-18 | 2000-04-27 | Boehringer Ingelheim Pharma | Stable aerosol formulations containing two or more bioactives used for pharmaceuticals |
US6238647B1 (en) * | 1991-12-12 | 2001-05-29 | Glaxo Group Limited | Aerosol formulations containing salmeterol xinafoate, an anticholinergic agent and tetrafluoroethane |
-
2001
- 2001-02-01 DE DE10104370A patent/DE10104370A1/en not_active Withdrawn
-
2002
- 2002-01-24 EP EP02722033A patent/EP1357976A2/en not_active Ceased
- 2002-01-24 WO PCT/EP2002/000704 patent/WO2002060533A2/en not_active Application Discontinuation
- 2002-01-24 AU AU2002252981A patent/AU2002252981A1/en not_active Abandoned
- 2002-01-24 CA CA002436510A patent/CA2436510A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6238647B1 (en) * | 1991-12-12 | 2001-05-29 | Glaxo Group Limited | Aerosol formulations containing salmeterol xinafoate, an anticholinergic agent and tetrafluoroethane |
DE19827178A1 (en) * | 1998-06-18 | 2000-04-27 | Boehringer Ingelheim Pharma | Stable aerosol formulations containing two or more bioactives used for pharmaceuticals |
Non-Patent Citations (1)
Title |
---|
CAZZOLA, M. ET AL.: "Incremental Benefit of Adding Oxitropium Bromide to Formoterol in Patients with Stable COPD", PULMONARY PHARMACOLOGY & THERAPEUTICS, vol. 12, 1999, pages 267 - 271, XP002210290 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9056100B2 (en) | 1999-07-14 | 2015-06-16 | Almirall, S.A. | Quinuclidine derivatives and medicinal compositions containing the same |
US9333195B2 (en) | 1999-07-14 | 2016-05-10 | Almirall, S.A. | Quinuclidine derivatives and medicinal compositions containing the same |
US9254262B2 (en) | 2008-03-13 | 2016-02-09 | Almirall, S.A. | Dosage and formulation |
Also Published As
Publication number | Publication date |
---|---|
DE10104370A1 (en) | 2002-08-08 |
WO2002060533A2 (en) | 2002-08-08 |
AU2002252981A1 (en) | 2002-08-12 |
CA2436510A1 (en) | 2002-08-08 |
EP1357976A2 (en) | 2003-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG106095A (en) | Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics | |
YU35503A (en) | Novel medicament compositions based on tiotropium salts and on salmeterol salts | |
WO2002047668A3 (en) | Novel medicament compositions based on anticholinesterase drugs and on ciclesonides | |
MXPA03011515A (en) | Novel pharmaceutical compositions based on anticholinergic agents, corticosteroids and betamimetic agents. | |
WO2002042462A3 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
EG24228A (en) | Tartrate salts of 5,8,18-trizatetracyclo[010.3.1.0.0]hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof | |
WO2001076575A3 (en) | The treatment of respiratory diseases | |
DE60202477D1 (en) | DEVICE FOR ADMINISTERING A SUBSTANCE | |
PL374325A1 (en) | Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof | |
CA2436540A1 (en) | Pharmaceutical compositions based on anticholinergics and corticosteroids | |
WO2003087049A3 (en) | Pharmaceutical combinations containing heterocyclic compounds and a novel anticholinergic agent | |
WO2003000172A3 (en) | Methods, pharmaceutical compositions, oral compositions, filters and tobacco products for preventing or reducing tobacco smoke-associated injury in the aerodigestive tract of a subject | |
WO2002060533A3 (en) | Pharmaceutical compositions containing beta-mimetic agents and having few side-effects | |
AP2004003045A0 (en) | Preparation compositions containing acid-unstable physiologically active compounds and process for producing the same. | |
EP1262197A3 (en) | Combination treatment for sleep disorders including sleep apnea | |
CA2417837A1 (en) | Compositions for ameliorating attention-deficient/hyperactivity disorder | |
WO2002053149A3 (en) | Medicament containing a polyamine as an active substance | |
CA2399709A1 (en) | Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers | |
IL168307A (en) | Compositions containing roflumilast and (r,r)-formoterol | |
BR0009080A (en) | Sleep apnea treatment method | |
HU0102987D0 (en) | Pharmaceutical composition for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient | |
WO2003030862A3 (en) | Anaesthetic compositions and method for their administration | |
CA2436537A1 (en) | Pharmaceutical compositions comprising tiotropium salts and antihistamines | |
WO2004048381A3 (en) | Pyrazoloazepine compounds as pharmaceutical agents | |
WO2002074034A3 (en) | Novel medicament compositions based on anticholinergic agents and endothelin antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002722033 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2436510 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2002722033 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWR | Wipo information: refused in national office |
Ref document number: 2002722033 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002722033 Country of ref document: EP |